<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049578</url>
  </required_header>
  <id_info>
    <org_study_id>WP40877</org_study_id>
    <nct_id>NCT04049578</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder</brief_title>
  <official_title>A Phase Ib, Multicenter, Open-Label, 6-Week Study With a 48-Week Extension to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children Ages 2-4 Years With Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a Phase Ib, multicenter, open-label study in children 2-4 years old with autism&#xD;
      spectrum disorder (ASD) to investigate the pharmacokinetics, safety, and tolerability of an&#xD;
      oral dose of balovaptan once a day (QD). The study was to consists of a 6-week treatment&#xD;
      period to evaluate the pharmacokinetics of balovaptan in 2 to 4 year old children followed by&#xD;
      an optional extension period of 48 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recent analysis of Phase II balovaptan data in paediatric ASD did not support the continuation&#xD;
    of this study. No new safety concerns were identified.&#xD;
  </why_stopped>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Actual">May 6, 2020</completion_date>
  <primary_completion_date type="Actual">April 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve at Steady State (AUCss) of Balovaptan</measure>
    <time_frame>Predose, 2, 4, 6 hours postdose at Week 2; predose at Week 6; predose at Week 12; predose at Week 24, predose at Week 54</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of Balovaptan</measure>
    <time_frame>Predose, 2, 4, 6 hours postdose at Week 2; predose at Week 6; predose at Week 12; predose at Week 24, predose at Week 54</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of M2 Metabolite, as Applicable</measure>
    <time_frame>Predose, 2, 4, 6 hours postdose at Week 2; predose at Week 6; predose at Week 12; predose at Week 24, predose at Week 54</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentation of M3 Metabolite</measure>
    <time_frame>Predose, 2, 4, 6 hours postdose at Week 2; predose at Week 6; predose at Week 12; predose at Week 24, predose at Week 54</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration Ratio of M2 to Balovaptan, as Applicable</measure>
    <time_frame>Predose, 2, 4, 6 hours postdose at Week 2; predose at Week 6; predose at Week 12; predose at Week 24, predose at Week 54</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration Ratio of M3 to Balovaptan</measure>
    <time_frame>Predose, 2, 4, 6 hours postdose at Week 2; predose at Week 6; predose at Week 12; predose at Week 24, predose at Week 54</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Up to approximately week 20</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Balovaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balovaptan</intervention_name>
    <description>Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.</description>
    <arm_group_label>Balovaptan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of ASD according to Diagnostic and Statistical Manual of Mental Disorders,&#xD;
             Fifth Edition (DSM-5) criteria for ASD. Diagnostics will be performed by a team of&#xD;
             autism experts and confirmed by Autism Diagnostic Observation ScheduleTM, Second&#xD;
             Edition (ADOS-2) criteria. The DSM-5 criteria for diagnosis of autism must be met with&#xD;
             the highest confidence in the opinion of the investigator. Children with ambiguous&#xD;
             diagnostic results cannot be enrolled in the study. If the ADOS-2 assessment has been&#xD;
             performed by a certified rater and documented within 12 months of the screening visit,&#xD;
             it is not mandatory to repeat it unless the subject was assessed below an age of 2&#xD;
             years.&#xD;
&#xD;
          -  Hearing and vision compatible with the study assessments, as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  Ability for subject and the caregiver to comply with the study protocol, in the&#xD;
             investigator's judgment&#xD;
&#xD;
          -  Availability of a parent or other reliable caregiver who is fluent in language of the&#xD;
             site and has frequent and sufficient contact with the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant psychiatric and/or neurologic comorbidity that may interfere&#xD;
             with the safety or efficacy endpoints in the view of the investigator&#xD;
&#xD;
          -  Clinically significant regression of any acquired language and motor function skills&#xD;
             in the opinion of the investigator throughout the subject's development&#xD;
&#xD;
          -  History of seizures with the exception of a single, non-complicated febrile seizure &gt;=&#xD;
             6 months before screening&#xD;
&#xD;
          -  Clinical diagnosis of peripheral neuropathy or signs and symptoms indicative of&#xD;
             peripheral neuropathy&#xD;
&#xD;
          -  Any clinically relevant cardiovascular disease&#xD;
&#xD;
          -  Confirmed elevation in cardiac troponin I (cTn I), high-sensitive cardiac troponin T&#xD;
             (hs cTn T), N-terminal pro-B-type natriuretic peptide (NT-proBNP) or, if conducted,&#xD;
             clinically relevant abnormality in Doppler echocardiogram&#xD;
&#xD;
          -  Confirmed clinically significant abnormality on ECG at screening, including, but not&#xD;
             limited to, a QT interval corrected through use of Fridericia's formula (QTcF) of &gt;=&#xD;
             450 ms, absence of dominating sinus rhythm, or second- or third-degree&#xD;
             atrioventricular block&#xD;
&#xD;
          -  Confirmed systolic or diastolic blood pressure above the 95th percentile or below the&#xD;
             5th percentile according to the Centers for Disease Control and Prevention (CDC) norm&#xD;
             tables referring to stature (height)-for-age percentiles&#xD;
&#xD;
          -  Confirmed heart rate: &gt;150 bpm in 2-year old children, &gt;135 bpm in 3-year old&#xD;
             children, or &gt;120 bpm in 4-year old children.&#xD;
&#xD;
          -  Concomitant disease or condition that could interfere with, or treatment of which&#xD;
             might interfere with, the conduct of the study; or discontinuation of prohibited&#xD;
             medication that might pose unacceptable risks to the subject in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  Evidence for current GI disease that would interfere with the conduct of the study or&#xD;
             pose unacceptable risks in the opinion of the investigator&#xD;
&#xD;
          -  History of coagulopathies, bleeding disorders, or blood dyscrasias&#xD;
&#xD;
          -  Positive serology for HIV-1 or HIV-2&#xD;
&#xD;
          -  Confirmed clinically significant abnormality in parameters of hematology, clinical&#xD;
             chemistry, coagulation, or urinalysis, specifically a confirmed absolute neutrophil&#xD;
             count (ANC) &lt;LLN Children with confirmed CPK elevations exceeding 2 x upper limit of&#xD;
             normal (ULN) will be excluded&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Clinically significant loss of blood within 3 months prior to screening&#xD;
&#xD;
          -  Unstable use of permitted medications for 4 weeks before screening&#xD;
&#xD;
          -  Use of prohibited medications within 30 days (or 5 times the half-life, whichever is&#xD;
             longer) prior to initiation of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Autism Research &amp; Resource Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center; Division of Child and Adolescent Psychiatry</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry Associates, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <results_first_submitted>September 21, 2020</results_first_submitted>
  <results_first_submitted_qc>September 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2020</results_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT04049578/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Balovaptan</title>
          <description>Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Balovaptan</title>
          <description>Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.45" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve at Steady State (AUCss) of Balovaptan</title>
        <time_frame>Predose, 2, 4, 6 hours postdose at Week 2; predose at Week 6; predose at Week 12; predose at Week 24, predose at Week 54</time_frame>
        <population>Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan</title>
            <description>Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve at Steady State (AUCss) of Balovaptan</title>
          <population>Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration of Balovaptan</title>
        <time_frame>Predose, 2, 4, 6 hours postdose at Week 2; predose at Week 6; predose at Week 12; predose at Week 24, predose at Week 54</time_frame>
        <population>Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan</title>
            <description>Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Balovaptan</title>
          <population>Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration of M2 Metabolite, as Applicable</title>
        <time_frame>Predose, 2, 4, 6 hours postdose at Week 2; predose at Week 6; predose at Week 12; predose at Week 24, predose at Week 54</time_frame>
        <population>Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan</title>
            <description>Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of M2 Metabolite, as Applicable</title>
          <population>Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentation of M3 Metabolite</title>
        <time_frame>Predose, 2, 4, 6 hours postdose at Week 2; predose at Week 6; predose at Week 12; predose at Week 24, predose at Week 54</time_frame>
        <population>Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan</title>
            <description>Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentation of M3 Metabolite</title>
          <population>Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration Ratio of M2 to Balovaptan, as Applicable</title>
        <time_frame>Predose, 2, 4, 6 hours postdose at Week 2; predose at Week 6; predose at Week 12; predose at Week 24, predose at Week 54</time_frame>
        <population>Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan</title>
            <description>Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration Ratio of M2 to Balovaptan, as Applicable</title>
          <population>Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration Ratio of M3 to Balovaptan</title>
        <time_frame>Predose, 2, 4, 6 hours postdose at Week 2; predose at Week 6; predose at Week 12; predose at Week 24, predose at Week 54</time_frame>
        <population>Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan</title>
            <description>Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration Ratio of M3 to Balovaptan</title>
          <population>Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <time_frame>Up to approximately week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan</title>
            <description>Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first study drug to the data cutoff date: 6 May 2020 (up to approximately 20 weeks)</time_frame>
      <desc>The safety population is defined as patients who received any amount of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Balovaptan</title>
          <description>Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated with 2 participants enrolled. Due to low enrollment number patient analysis are not provided to protect participant confidentiality.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

